DOCSLIB.ORG

Copyrighted Material

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Copyrighted Material Index Note: Page numbers in italics refer to figures; page numbers in bold refer to tables Abelson 1 breakapart cluster fusion gene, 508 case study, 378, 391, 391–392 phenotypic studies, 283–284, 286, 287, 288, acitretin, 18 pathology, 381, 391, 392 289 acquired immunodeficiency syndrome (AIDS), alemtuzumab post-transplant, 281, 288–289, 288–289, 301, plasmablastic lymphoma, 427, 427 cutaneous T cell lymphoma, 18 302, 303, 303–304, 419 acral pseudolymphomatous angiokeratomas of Sézary syndrome, 18 primary, 281 children (APACHE), 67 T cell prolymphocytic leukemia, 453 pyogenic, 282 ACT-1 see CD25 antigen aleukemic leukemia cutis, 507 sarcomatoid see sarcomatoid anaplastic large actinic dermatitis, chronic, 52 ALK see anaplastic lymphoma kinase (ALK) cell lymphoma actinic prurigo, 52 ALK-1 breakapart probe, 13 secondary, 281 actinic reticuloid, 52, 356 allergic contact dermatitis, 37–39 small cell see small cell anaplastic large cell activation/proliferation markers clinical features, 37, 38 lymphoma anaplastic large cell lymphoma, 283 differential diagnosis, 39 type I cells, 281, 287, 288 definitions, 12 histomorphology, 37 type II cells, 281, 289, 297 acute monoblastic and monocytic leukemia, 535 pathogenesis, 39 unusual histologic variants, 282 acute monoblastic leukemia, 508, 513 allogeneic bone marrow transplant variants/subtypes, 280, 280 acute monocytic leukemia, 509 acute graft-versus-host disease, 44 anaplastic lymphoma kinase (ALK) acute myelogenous leukemia, 508 subcutaneous panniculitis-like T cell anaplastic large cell lymphoma, 280, 282, 283, case studies, 517, 517 lymphoma, 336 286 light microscopic findings, 509 allogeneic hematopoietic stem cell detection methods, 284 subtypes, 507, 534, 535 transplantation (allo-HSCT), cutaneous T lymphomatoid papulosis, 277, 281 acute myeloid leukemia, 509, 534 cell lymphoma, 20 rearrangement, 308 acute myelomonocytic leukemia, 535 alopecia, syringolymphoid hyperplasia with anaplastic lymphoma kine-positive diffuse large acute promyelocytic leukemia (APL), 534, 535 see syringolymphoid hyperplasia with B cell lymphoma, 283 adipocyte rimming alopecia anaplastic plasmacytoma see plasmablastic γ δ T cell lymphoma, 407, 410, 411 alopecia mucinosa, 98, 98–99 lymphoma subcutaneous panniculitis-like T cell case studies, 111–114, 111–114, 115, 117, 117 angiocentric cutaneous T cell lymphoma of lymphoma, 336, 343, 346 differential diagnosis, 98, 99 childhood, 416 adnexotropic mycosis fungoides, 240–241, 250, follicular mycosis fungoides, 240 angiocentric immunoproliferative lesions (AIL), 253 light microscopic findings, 99, 111, 113, 117 499 adnexotropic T cell dyscrasia, case study, 115, molecular studies, 99, 114, 116, 126 angiocentric T cell lymphoma, differential 115–116 phenotypic studies, 99, 112, 113, 114 diagnosis, 501 adult T cell leukemia/lymphoma, 473, 473–485 amyloidosis, nodular, 143 angioimmunoblastic lymphadenopathy with acute, 473, 473–475, 474, 479–480, 479–481 anaplastic large cell lymphoma, 280, 280–282, dysproteinemia see angioimmunoblastic T case studies, 477–483, 477–483 281 cell lymphoma chronic, 474, 474 activation antigens, 283 angioimmunoblastic T cell lymphoma, 486, clinical features, 473, 473–474 breast-implant-associated, 282 486–498, 489 differential diagnosis, 454, 474 case studies, 33, 33, 286–289, 286–289 architectural growth patterns, 487 follicular mucinosis, 475 categorization, 281 autoimmune diathesis, 486 HTLV-1-associated post-transplant, 419COPYRIGHTEDCD8-positive MATERIALcase studies, 491–496, 491–496 immune suppression, 474 case study, 297, 297 clinical features, 486, 486–487 lymphomatous, 473, 474, 482, 482, 483 phenotypic studies, 283, 284, 293, 294, 295, composite lymphoma, 487 pathogenesis, 475–476 297 differential diagnosis, 487 pathology, 474–475, 477, 479, 480 cytogenetics, 284, 302 diffuse large B cell lymphoma, 487 phenotypic studies, 475, 478 differential diagnosis, 316, 319, 437, 513 drug-induced, 486 prognosis, 474 intravascular, 219–220, 282–283 Epstein–Barr virus, 486–487, 488, 489 skin lesions, 474 light microscopic findings, 281–282, 286, 287, light microscopic findings, 487, 492, 495 smoldering, 474, 474, 477, 477, 478 288, 289 lymph node changes, 487, 491, 495 treatment, 475 lymphomatoid papulosis vs., 280 molecular studies, 488–489 236A/F7 see Fox P3 molecular studies, 301 pathogenesis, 489–490 aggressive natural killer cell lymphoma, 378, myxoid, 283, 305, 305, 306 phenotypic studies, 488, 491 380, 380, 391 pathogenesis, 284–285 primary cutaneous B cell lymphoma, 487 The Cutaneous Lymphoid Proliferations: A Comprehensive Textbook of Lymphocytic Infiltrates of the Skin, Second Edition. Cynthia M. Magro, A. Neil Crowson and Martin C. Mihm. © 2016 John Wiley & Sons, Inc. Published 2016 by John Wiley & Sons, Inc. 541 bindex 541 19 November 2015 7:21 PM 279mm×216mm 542 Index angioimmunoblastic T cell (continued) bax, mycosis fungoides, 257 Berti’s lymphoma see primary cutaneous B cell(s) aggressive epidermotropic cytotoxic skin findings, 487, 491, 494 clonality assessment, 28 CD8+ T cell lymphoma therapy, 486 differentiation stage, 138 beta 1 integrin subunit see CD29 antigen vascular changes, 487, 494 lymphocytoma cutis, 66 bexarotene angioinvasion marginal zone lymphoma, 136, 145 adverse events, 17 γ δ T cell lymphoma, 409 paraffin-embedded tissue panels, 12 cutaneous T cell lymphoma, 15–16, 17 nasal natural killer cell/T cell lymphoma, 388 proliferation, 138 denileukin diftitox and, 17–18 type E lymphomatoid papulosis, 276, 278 V-D-J rearrangement, 23 mycosis fungoides, 15–16 angiolymphoid hyperplasia with eosinophilia B cell chronic lymphocytic leukemia (B-CLL), safety/efficacy, 16 (ALHE), 67–68 449–452, 450, 469 BF-1 antibody angiotropism, 169 case studies, 455–461, 455–461 definition, 9 γ δ T cell lymphoma, 407, 409 clinical features, 449–450 γ δ T cell lymphoma, 408, 411 annular lichenoid dermatosis of youth, 92 cytogenetics, 451, 467 Binet staging system, chronic lymphocytic antibodies, 13 molecular studies, 451 leukemia, 449 antibody drug conjugates (ADC), 19 morphology, 450, 455, 456, 457, 458, 459, 460, Birbeck granules, Langerhans sarcoma, 512 antihistamines 461 blastic marginal zone lymphoma, 140, 161, 162, marginal zone lymphoma, 134 pathogenesis, 452 188, 189, 194–195 reactive lymphoid hyperplasia induction, 134 phenotype, 451, 457, 459, 461 case study, 161, 161–163 antiphospholipid antibody syndrome, 45 prognosis, 450, 451 cytogenetic profile, 163, 194 anti-Ro-associated systemic lupus B cell hyperplasia de novo, 140, 194 erythematosus, 46 mycosis fungoides, 251 light microscopic findings, 140, 226, 229, 232 clinical features, 49 primary cutaneous CD4+ small/medium- phenotypic profile, 140 histopathology, 50 sized pleomorphic T cell lymphoma, 317 prognosis, 194 immunofluorescent findings, 50 B-cell lymphoid hyperplasia, 138 reactive germinal centers, 190 antithymocyte autoantibody, chronic B cell markers, definition, 10–11 subtypes, 140, 194 lymphocytic leukemia, 452 B cell neoplasms, classification, 138 blastic NK cell lymphoma see blastic antivirals, post-transplant lymphoproliferative bcl-1 plasmacytoid dendritic cell neoplasm disease, 418 blastoid mantle cell lymphoma, 230, 232 blastic NK-like T cell lymphoma see blastic API2 MALT1 fusion probe, 13 definition, 10 plasmacytoid dendritic cell neoplasm API2-MALT1 fusion protein, marginal zone mantle cell lymphoma, 226, 227, 233 blastic plasmacytoid dendritic cell neoplasm, lymphoma, 138 bcl-2 377, 379, 382–383, 383, 507, 510 apoptosis blastic marginal zone lymphoma, 162, 195 case study, 399, 399–400 acute graft-versus-host disease, 45 chronic lymphocytic leukemia, 451 light microscopic findings, 383 CD10 antigen, 196, 488 definition, 10 molecular studies, 383 mycosis fungoides, 257 diffuse large B cell lymphoma, leg type, 190, phenotypic studies, 383, 399, 400 systems, 257 202 blastoid mantle cell lymphoma, 226 apoptosis regulator B cell lymphoma 10 (BCL10) double-hit lymphoma, 197 case studies, 229, 229, 230, 232, 232 see Bcl-10 marginal zone lymphoma, 137, 150 cytogenetic studies, 233 APRIL, chronic lymphocytic leukemia, 451 precursor B cell lymphoblastic lymphoma, 212 BLIPM-1, diffuse large B cell lymphoma, leg arthropod-bite responses, 39 primary cutaneous follicle center lymphoma, type, 193 ataxia telangiectasia, 453 171, 172–173, 175, 183 BOB-1, lymphocyte-predominant Hodgkin ataxia telangiectasia mutated gene/protein bcl-2 IgH fusion probe, 13, 195 lymphoma, 437 (ATM) bcl-6 body-surface area (BSA) mantle cell lymphoma, 227, 228 definition, 10 calculation, 4, 245 T cell prolymphocytic leukemia, 454 diffuse large B cell lymphoma, 190 mycosis fungoides, 4, 236 atopic dermatitis, 41, 242, 244 diffuse large B cell lymphoma, leg type, 193 bone marrow erythrodermic, 244 follicular helper T cell lymphoma, 317 mycosis fungoides, 254 atypical fibroxanthoma, 515 Hodgkin lymphoma, 437, 442 myelodysplastic syndrome, 508 atypical lymphocytic lobular panniculitis, 100, marginal zone lymphoma, 137 bone marrow biopsy, 5 100–101, 101, 336, 337–338 primary cutaneous follicle center lymphoma, borderline CD30-positive lymphoproliferative case studies, 109, 109–110, 118, 118, 345, 173, 180, 183, 190, 191, 193, 204 disorders, 279, 290, 290, 291, 296 345–346 BCL7a, mycosis fungoides, 258 Borrelia burgdorferi differential diagnosis, 101, 337–338, 408 Bcl-10 marginal zone lymphoma, 138 light microscopic findings, 101,107–108, 109, 118 definition, 10 morphea, 55 molecular studies, 101, 127, 129 marginal zone lymphoma, 137 BRAF mutation, Langerhans cell histiocytosis, morphology,
Load more

Recommended publications
  • 2U11/13U195 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ n n 20 October 2011 (20.10.2011) 2U11/13U195 Al (51) International Patent Classification: ka Pharmaceutical Co., Ltd., 1-7-1, Dosho-machi, Chuo- C12P 19/34 (2006.01) C07H 21/04 (2006.01) ku, Osaka-shi, Osaka 541-0045 (JP). (21) International Application Number: (74) Agents: KELLOGG, Rosemary et al; Swanson & PCT/US201 1/032017 Bratschun, L.L.C., 8210 SouthPark Terrace, Littleton, Colorado 80120 (US). (22) International Filing Date: 12 April 201 1 (12.04.201 1) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, English (25) Filing Language: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 61/323,145 12 April 2010 (12.04.2010) US KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (71) Applicants (for all designated States except US): SOMA- ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, LOGIC, INC. [US/US]; 2945 Wilderness Place, Boulder, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, Colorado 80301 (US). OTSUKA PHARMACEUTI¬ SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, CAL CO., LTD.
    [Show full text]
  • Dermatology in Geriatrics a Gandhi, M Gandhi, S Kalra
    The Internet Journal of Geriatrics and Gerontology ISPUB.COM Volume 5 Number 2 Dermatology in Geriatrics A Gandhi, M Gandhi, S Kalra Citation A Gandhi, M Gandhi, S Kalra. Dermatology in Geriatrics. The Internet Journal of Geriatrics and Gerontology. 2009 Volume 5 Number 2. Abstract Over the past few years the world's population has continued on its remarkable transition from a state of high birth and death rates to one characterized by low birth and death rates. Consequently, primary care physicians and dermatologists will see more elderly patients presenting age related dermatological conditions.As people age, their chances of developing skin-related disorders increase due to multiple underlying medical conditions i.e. diabetes mellitus, atherosclerosis and decreased immunity. Common skin disorders found in the elderly individual are xerosis, pruritus, eczematous dermatitis, purpura, chronic venous insufficiency, psychocutaneous disorders etc. Caregivers and medical personnel can help decrease or prevent the development of many skin disorders in the elderly by addressing several factors i.e patient’s nutritional status, medical history, current medications, allergies, physical limitations, mental state, and personal hygiene and for specific underlying etiologies; several pharmacological treatment choices are suggested. INTRODUCTION and assisted living facilities3 .Caregivers and medical The famous old saying OLD IS GOLD doesn’t apply to personnel can help decrease or prevent the development of human skin as elderly people are recognized by their many skin disorders in the elderly by addressing several wrinkled and dull skin. The population is getting older, with factors i.e patient’s nutritional state, medical history, current a greater percentage of the population in the over-65 age medications, allergies, physical limitations, mental state, and group.
    [Show full text]
  • General Aspects 14 Niels K
    14_199_254* 05.11.2005 10:15 Uhr Seite 201 Chapter 14 General Aspects 14 Niels K. Veien Contents 14.1 Introduction . 201 14.4.2.1 Cement Ulcerations . 224 14.4.2.2 Pigmented Contact Dermatitis . 225 14.2 The Medical History of the Patient . 202 14.4.2.3 Caterpillar Dermatitis and Irritant Dermatitis 14.2.1 History of Hereditary Diseases . 202 from Plants and Animals . 225 14.2.2 General Medical History . 202 14.4.2.4 Head and Neck Dermatitis . 225 14.2.3 History of Previous Dermatitis . 203 14.4.2.5 Dermatitis from Transcutaneous Delivery 14.2.4 Time of Onset . 203 Systems . 225 14.2.5 History of Aggravating Factors . 204 14.4.2.6 Berloque Dermatitis . 226 14.2.6 Course of the Dermatitis . 205 14.4.2.7 Stomatitis due to Mercury or Gold Allergy . 226 14.2.7 Types of Symptoms . 205 14.5 Regional Contact Dermatitis . 226 14.3 Clinical Features of Eczematous Reactions . 206 14.5.1 Dermatitis of the Scalp . 226 14.3.1 Acute and Recurrent Dermatitis . 206 14.5.2 Dermatitis of the Face and Neck . 228 14.3.2 Chronic Dermatitis . 210 14.5.2.1 The Lips . 230 14.3.3 Nummular (Discoid) Eczema . 211 14.5.2.2 The Eyes and Eyelids . 230 14.3.4 Secondarily Infected Dermatitis . 211 14.5.2.3 The Ear . 231 14.3.5 Clinical Features of Contact Dermatitis 14.5.3 Dermatitis of the Trunk . 232 in Specific Groups of Persons . 212 14.5.3.1 The Axillary Region .
    [Show full text]
  • Id Reaction Associated with Red Tattoo Ink
    CASE LETTER Id Reaction Associated With Red Tattoo Ink Alexandra Price, MD; Masoud Tavazoie, MD, PhD; Shane A. Meehan, MD; Marie Leger, MD, PhD 1 month later, she developed pruritic papulonodular PRACTICE POINTS lesions localized to the red-pigmented areas of the tattoo. • Hypersensitivity reactions to tattoo pigment are on Concomitantly, the patient developed a similar eruption the rise due to the increasing popularity and preva- confined to areas of red pigment in a polychromatic tattoo lence of tattoos. Systemic allergic reactions to tattoo on the right upper arm that she had obtained 10 years ink are rare but can cause considerable morbidity. prior. She was treated with intralesional triamcinolone to • Id reaction, also known as autoeczematization or several of the lesionscopy on the right dorsal foot with some autosensitization, is a reaction that develops distant benefit; however, a few days later she developed a gener- to an initial site of infection or sensitization. alized, erythematous, pruritic eruption on the back, abdo- • Further investigation of color additives in tattoo pig- men, arms, and legs. Her medical history was remarkable ments is warranted to better elucidate the compo- only for mild iron-deficiency anemia. She had no known nents responsible for cutaneous allergic reactions drugnot allergies or history of atopy and was not taking any associated with tattoo ink. medications prior to the onset of the eruption. Skin examination revealed multiple, well-demarcated, eczematous papulonodules with surrounding erythema To the Editor: Doconfined to the red-pigmented areas of the tattoo on Although relatively uncommon, hypersensitivity reactions the right dorsal foot, with several similar lesions on to tattoo pigment are on the rise due to the increasing the surrounding nontattooed skin (Figure 1).
    [Show full text]
  • 1 Skin Infections Among Elderly Living in Long-Term Care Facilities
    1 Skin Infections Among Elderly Living in Long-term Care Facilities Michelle K. Kotti, BSN, MSN, FNP-BC University of Texas at Austin Introduction In the U.S. today, the population of individuals who are 65 years of age and older is increasing (U.S. Census Bureau, 2018), and nurses, as frontline health care providers, are increasingly becoming a conduit for healthy senior living. This module therefore focuses specifically on adults ≥65 years of age with skin infections, a healthcare concern that is especially important among those who are living in long-term care facilities (LTCF). Recent articles on cutaneous infections among those in LCTF are few; indeed more studies of skin infections have been conducted in Europe and Asia than in the U.S. Cutaneous infections are the third most common infection diagnosed in LTCF, preceded only by respiratory infections and infections of the urinary tract (Jump et al., 2008). The cutaneous infections commonly mentioned are cellulitis, angular cheilitis, folliculitis, fungal infections, impetigo, herpes simplex/zoster, and scabies (de Castro & Ramos-e-Silva, 2018). In addition, the skin reflects individuals’ internal health, with a unique and sensitive ability to present manifestations of underlying diseases and even malignancy (Hall, 2006). As a result, the information provided here may lead to additional questions, but it will facilitate our ability to recognize the early signs and symptoms of skin infections so that we can make a difference. Prevention is one of the best defenses. Of course the many health issues associated with the aging process and the immune system’s decline can be a challenge as well (de Castro & Ramos-e-Silva, 2018).
    [Show full text]
  • Mallory Prelims 27/1/05 1:16 Pm Page I
    Mallory Prelims 27/1/05 1:16 pm Page i Illustrated Manual of Pediatric Dermatology Mallory Prelims 27/1/05 1:16 pm Page ii Mallory Prelims 27/1/05 1:16 pm Page iii Illustrated Manual of Pediatric Dermatology Diagnosis and Management Susan Bayliss Mallory MD Professor of Internal Medicine/Division of Dermatology and Department of Pediatrics Washington University School of Medicine Director, Pediatric Dermatology St. Louis Children’s Hospital St. Louis, Missouri, USA Alanna Bree MD St. Louis University Director, Pediatric Dermatology Cardinal Glennon Children’s Hospital St. Louis, Missouri, USA Peggy Chern MD Department of Internal Medicine/Division of Dermatology and Department of Pediatrics Washington University School of Medicine St. Louis, Missouri, USA Mallory Prelims 27/1/05 1:16 pm Page iv © 2005 Taylor & Francis, an imprint of the Taylor & Francis Group First published in the United Kingdom in 2005 by Taylor & Francis, an imprint of the Taylor & Francis Group, 2 Park Square, Milton Park Abingdon, Oxon OX14 4RN, UK Tel: +44 (0) 20 7017 6000 Fax: +44 (0) 20 7017 6699 Website: www.tandf.co.uk All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP. Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention.
    [Show full text]
  • Pediatric Allergy/Immunology/Rheumatology
    Pediatric Allergy/Immunology/Rheumatology Akaluck Thatayatikom, MD Associate Professor Director, Division of Allergy/Immunology/Rheumatology Department of Pediatrics, University of Kentucky Disclosure: None Objectives Upon completion of this session, participants should be able t o und erst and , recogni ze and manage th e following conditions: • Common allergic diseases in children – Allergic Rhinoconjunctivitis – Atopic dermatitis – Food allergy • Common primary Immunodeficiency • Common rheumatologic diseases in children – Acute arthritis: ARF, reactive arthritis, Transient toxic synovitis, – Chronic arthritis: JRA (JIA) Allergic Diseases Asthma Reactions to foods Rhinitis Eczema/ Contact dermatitis Allergic Mechanisms Urticaria Reactions to Drugs Angioedema Anaphylaxis Allergy and allergic diseases 2nd edition Atopy and Atopic Diseases • Atopy: A genetically predisposed diathesis manifesting as exaggeratdted responses (eg. bronc hocons tititriction, I IEgE production, vasodilation, pruritus) to a variety of environmental stimuli (irritants, allergens, and mib)icrobes) • Atopy is fundamental to the pathogenesis of atopic allergic diseases; allergic rhinoconjunctivitis, asthma, food allergy, atopic dermatitis. • Not every atopic child develops atopic diseases • Not everyyp child with atopic disease is ato py. Atopy and Atopic Diseases • Objective evidence of being atopy: – Elevated total IgE in serum for age – Specific IgE to specific allergens: • In vivo: Specific IgE on mast cells (skin) – Prick skin test – Intradermal skin test •
    [Show full text]
  • Allergic Contact Dermatitis in Women
    Allergic Contact Dermatitis Mari Paz Castanedo Tardan, MD Assistant Professor of Dermatology [email protected] Disclosure • I have no conflicts of interest to disclose. Objectives • What is Allergic Contact Dermatitis? Describe • Pathogenesis • Epidemiology Review • Clinical presentation • Diagnosis Discuss • Common and relevant contact allergens What is it? When the skin comes in contact with external agents, many adverse events can occur including contact dermatitis which can be either irritant or allergic • Irritant contact dermatitis (ICD) accounts for ~ 80% • Allergic contact dermatitis (ACD) accounts for ~ 20% Pathogenesis ACD is a delayed, type IV, T-cell mediated hypersensitivity reaction within the skin that results from contact between the skin and an allergenic external agent • Previous exposure and sensitization to a specific chemical IS required • 2 distinct phases: • Sensitization phase (when the individual first comes in contact with the allergenic chemical) • Elicitation phase Sensitization Phase Hapten + skin proteins = Antigen Keratinocytes IL-1B, TNFa Langerhans cell Antigen Uptake Sensitization Phase Epidermis LC migrates out of the epidermis and into the dermis (TNF-a) Matures and processes the antigen Naïve T-cell (IL-1B) Lymph vessel Clonal expansion Regional lymph node Effector T-cell Elicitation Phase • If immunologic memory develops, when a sensitized individual is subsequently re-exposed to an antigen, the effector/memory T-cells recognize the antigen, proliferate and call in other inflammatory cells. • Once
    [Show full text]
  • (Autoeczematisation) Reactions in a Case of Diaper Dermatitis Candidiasis
    CASE REPORT Autosensitisation (Autoeczematisation) reactions in a case of diaper dermatitis candidiasis Anca Chirac1, Piotr Brzezinski2, Anca E Chiriac3, Liliana Foia4, Tudor Pinteala3 1Department of Dermatology, Nicolina Medical Center, Strada Hatman Sendrea nr 2, 2Department of Dermatology, 6th Military Support Unit, Ustka, Poland, 3Student, University of Medicine and Pharmacy “Grigore T. Popa”, Str. Universitatii nr. 16, Iasi, Romania, 4Department of Dermatology, University of Medicine and Pharmacy “Grigore T. Popa”, Str.Universitatii nr. 16, Iasi, Romania, Europe ABSTRACT Diaper dermatitis is the most common cutaneous diagnosis in infants. Most cases are associated with the yeast colonisation of Candida or diaper dermatitis candidiasis (DDC). Address for correspondence: It is an irritating and inflammatory acute dermatitis in the perineal and perianal areas Prof. Liliana Foia, resulting from the occlusion and irritation caused by diapers. Autoeczematization to Department of Surgery, a distant focus of dermatophyte infection very rarely presents as DDC. We present a University of Medicine and 1-month-old boy with lesion on diaper area (gluteal area, perineum, groin and genitalia) Pharmacy “Grigore T. Popa”, and with clusters of pustules and vesicles on a large erythematous base over the dorsal Universitatii Str. Nr. 16, Iasi, area of both hands. Romania, Europe. E-mail: [email protected] Key words: Candida, Candidiasis, Candida albicans, diaper dermatitis, ID reaction INTRODUCTION ID reaction to a distant focus of dermatophyte infection very rarely presents as DDC. Diaper dermatitis (DD) is the most common cutaneous diagnosis in infants, particularly at 1–15 months of age. We present a 1-month-old boy with lesion on diaper area Most cases are associated with the yeast colonisation (gluteal area, perineum, groin and genitalia) and with of Candida or diaper dermatitis candidiasis (DDC).
    [Show full text]
  • WO 2018/005695 Al O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2018/005695 A l 0 4 January 2018 (04.01.2018) W ! P O PCT (51) International Patent Classification: (72) Inventors: BASTA, Steven; 590 Berkeley Avenue, Menlo A61K 31/4035 (2006.01) A61P 17/04 (2006.01) Park, CA 94025 (US). JOING, Mark; 936 Clara Drive, Pa A61K 45/06 (2006.01) lo Alto, CA 94303 (US). ZHANG, Xiaoming; 1089 Rem- sen Court, Sunnyvale, CA 94087 (US). KWON, Paul; 3349 (21) International Application Number: Deer Hollow Dr, Danville, CA 94506 (US). PCT/US20 17/039829 (74) Agent: SILVERMAN, Lisa, N.; Morrison & Foerster LLP, (22) International Filing Date: 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). 28 June 2017 (28.06.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/356,280 29 June 2016 (29.06.2016) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/356,291 29 June 2016 (29.06.2016) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/356,301 29 June 2016 (29.06.2016) us MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/356,294 29 June 2016 (29.06.2016) us OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/356,286 29 June 2016 (29.06.2016) us SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, 62/356,271 29 June 2016 (29.06.2016) us TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Jennifer a Cafardi the Manual of Dermatology 2012
    The Manual of Dermatology Jennifer A. Cafardi The Manual of Dermatology Jennifer A. Cafardi, MD, FAAD Assistant Professor of Dermatology University of Alabama at Birmingham Birmingham, Alabama, USA [email protected] ISBN 978-1-4614-0937-3 e-ISBN 978-1-4614-0938-0 DOI 10.1007/978-1-4614-0938-0 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2011940426 © Springer Science+Business Media, LLC 2012 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identifi ed as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) Notice Dermatology is an evolving fi eld of medicine.
    [Show full text]
  • Atopic Dermatitis in Adults: a Diagnostic Challenge Silvestre Salvador JF, Romero-Pérez D, Encabo-Durán B
    REVIEWS Atopic Dermatitis in Adults: A Diagnostic Challenge Silvestre Salvador JF, Romero-Pérez D, Encabo-Durán B Servicio de Dermatología, Hospital General Universitario de Alicante, Alicante, Spain J Investig Allergol Clin Immunol 2017; Vol. 27(2): 78-88 doi: 10.18176/jiaci.0138 Abstract Atopic dermatitis (AD) has a prevalence of 1%-3% in adults. Adult-onset AD has only been defined recently, and lack of familiarity with this condition and confusion regarding the appropriate terminology persist. AD may first appear in childhood or de novo in adults and is characterized by pronounced clinical heterogeneity. The disease often deviates from the classic pattern of flexural dermatitis, and there are forms of presentation that are specific to adults, such as head-and-neck dermatitis, chronic eczema of the hands, multiple areas of lichenification, or prurigo lesions. Although diagnosis is clinical, adult-onset AD frequently does not fit the traditional diagnostic criteria for the disease, which were developed for children. Thus, AD is often a diagnosis of exclusion, especially in de novo cases. Additional diagnostic tests, such as the patch test, prick test, skin biopsy, or blood test, are usually necessary to rule out other diseases or other types of eczema appearing concomitantly with AD. This article presents an update of the different forms of clinical presentation for AD in adults along with a proposed diagnostic approach, as new treatments will appear in the near future and many patients will not be able to benefit from them unless they are properly diagnosed. Key words: Atopic dermatitis. Adult. Diagnosis. Patch testing. Prick testing.
    [Show full text]